To model IBD and SpA, we chose the TNFΔARE/+ transgenic murine model given the success of TNF targeting treatments in in these diseases and our observation of increased TNF production by stimulated IELs in SpA and IBD (18). The gene discussed is TNF; the disease is inflammatory bowel disease.